FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382806979> ?p ?o ?g. }

• W4382806979 endingPage "S105" @default.
• W4382806979 startingPage "S104" @default.
• W4382806979 abstract "GEM/nab-PTX (GnP) or (modified) FOLFIRINOX [(m)FFX] is recommended as primary chemotherapy for metastatic pancreatic cancer, however second-line treatment is controversial. There is no clear consensus on the second-line treatment following progression on GnP for metastaic pancreatic cancer, especially with regard to the choice between (m) FFX and 5-FU/LV/nal-IRI (NAPOLI). Therefore, we retrospectively reviewed the clinical outcomes of second-line treatment of metastatic pancreatic cancer treated with GnP as primary therapy at our institution. From January 2015 to August 2021, 263 metastatic pancreatic cancer patients received GnP as primary treatment and were received second-line treatment at our institution. We analyzed the clinical outcomes of 107 patients who received mFFX and 40 patients who received NAPOLI as second-line treatment after GnP therapy. The results were shown in the order of mFFX group vs. NAPOLI group. In terms of background factors, only age [median 63 years (range 35-76) vs. 75 (38-80) p < 0.01] and the proportion of patients who did not respond to GnP (21.5% vs. 47.5% p < 0.01) were significantly different. There were no statistically significant differences in other factors including gender, body mass index, performance status, comorbidities, diabetes mellitus, histological diagnosis, number of metastatic organs, percentage of postoperative recurrence, biliary drainage, serum albumin level, and serum CA19-9 level at the initiation of second-line treatment. Median overall survival (OS) after initiation of second-line treatment was 7.2 (95% CI: 6.4-8.4) months vs. 7.9 (5.3-10.3) months p=0.98, progression-free survival (PFS) was 3.6 (2.8-5.1) months vs. 5.1 (2.7-6.5) months p=0.85, and the rate of grade 3 or higher adverse events was 29.9% vs. 20.0% p=0.30. Propensity score matching was performed including all of the aforementioned background ifactors, and comparisons of clinical outcomes were made with matched pair cohort, including 17 patients in each group. OS was 7.0 (4.0-14.2) months vs. 8.9 (2.8-NA) months p=0.73, PFS was 3.7 (2.2-12.2) months vs. 4.4 (1.3-6.7) months p=0.30, and the rate of grade 3 or higher adverse events was 29.4% vs. 23.5% p=1.0 in matched pair cohort. NAPOLI tended to be selected over mFFX for second-line treatment after GnP in older patients and in patients who did not respond to GnP. Howerver, there were also no statistically significant differences in clinical outcomes and adverse event rates in the matched pair cohort." @default.
• W4382806979 created "2023-07-02" @default.
• W4382806979 creator A5005262911 @default.
• W4382806979 creator A5015118724 @default.
• W4382806979 creator A5027529203 @default.
• W4382806979 creator A5030913868 @default.
• W4382806979 creator A5036674180 @default.
• W4382806979 creator A5038392685 @default.
• W4382806979 creator A5039878364 @default.
• W4382806979 creator A5050468802 @default.
• W4382806979 creator A5054771200 @default.
• W4382806979 creator A5055286517 @default.
• W4382806979 creator A5058972080 @default.
• W4382806979 creator A5068906545 @default.
• W4382806979 creator A5080299485 @default.
• W4382806979 creator A5086074088 @default.
• W4382806979 creator A5089619078 @default.
• W4382806979 creator A5090787337 @default.
• W4382806979 date "2023-06-01" @default.
• W4382806979 modified "2023-09-24" @default.
• W4382806979 title "P-252 Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer" @default.
• W4382806979 doi "https://doi.org/10.1016/j.annonc.2023.04.308" @default.
• W4382806979 hasPublicationYear "2023" @default.
• W4382806979 type Work @default.
• W4382806979 citedByCount "0" @default.
• W4382806979 crossrefType "journal-article" @default.
• W4382806979 hasAuthorship W4382806979A5005262911 @default.
• W4382806979 hasAuthorship W4382806979A5015118724 @default.
• W4382806979 hasAuthorship W4382806979A5027529203 @default.
• W4382806979 hasAuthorship W4382806979A5030913868 @default.
• W4382806979 hasAuthorship W4382806979A5036674180 @default.
• W4382806979 hasAuthorship W4382806979A5038392685 @default.
• W4382806979 hasAuthorship W4382806979A5039878364 @default.
• W4382806979 hasAuthorship W4382806979A5050468802 @default.
• W4382806979 hasAuthorship W4382806979A5054771200 @default.
• W4382806979 hasAuthorship W4382806979A5055286517 @default.
• W4382806979 hasAuthorship W4382806979A5058972080 @default.
• W4382806979 hasAuthorship W4382806979A5068906545 @default.
• W4382806979 hasAuthorship W4382806979A5080299485 @default.
• W4382806979 hasAuthorship W4382806979A5086074088 @default.
• W4382806979 hasAuthorship W4382806979A5089619078 @default.
• W4382806979 hasAuthorship W4382806979A5090787337 @default.
• W4382806979 hasBestOaLocation W43828069791 @default.
• W4382806979 hasConcept C121608353 @default.
• W4382806979 hasConcept C126322002 @default.
• W4382806979 hasConcept C141071460 @default.
• W4382806979 hasConcept C143998085 @default.
• W4382806979 hasConcept C2776694085 @default.
• W4382806979 hasConcept C2776907518 @default.
• W4382806979 hasConcept C2777148230 @default.
• W4382806979 hasConcept C2780210213 @default.
• W4382806979 hasConcept C2780962732 @default.
• W4382806979 hasConcept C526805850 @default.
• W4382806979 hasConcept C71924100 @default.
• W4382806979 hasConcept C90924648 @default.
• W4382806979 hasConceptScore W4382806979C121608353 @default.
• W4382806979 hasConceptScore W4382806979C126322002 @default.
• W4382806979 hasConceptScore W4382806979C141071460 @default.
• W4382806979 hasConceptScore W4382806979C143998085 @default.
• W4382806979 hasConceptScore W4382806979C2776694085 @default.
• W4382806979 hasConceptScore W4382806979C2776907518 @default.
• W4382806979 hasConceptScore W4382806979C2777148230 @default.
• W4382806979 hasConceptScore W4382806979C2780210213 @default.
• W4382806979 hasConceptScore W4382806979C2780962732 @default.
• W4382806979 hasConceptScore W4382806979C526805850 @default.
• W4382806979 hasConceptScore W4382806979C71924100 @default.
• W4382806979 hasConceptScore W4382806979C90924648 @default.
• W4382806979 hasLocation W43828069791 @default.
• W4382806979 hasOpenAccess W4382806979 @default.
• W4382806979 hasPrimaryLocation W43828069791 @default.
• W4382806979 hasRelatedWork W2012954058 @default.
• W4382806979 hasRelatedWork W2138640290 @default.
• W4382806979 hasRelatedWork W2599910524 @default.
• W4382806979 hasRelatedWork W2910090032 @default.
• W4382806979 hasRelatedWork W2910998150 @default.
• W4382806979 hasRelatedWork W2941837211 @default.
• W4382806979 hasRelatedWork W3008650849 @default.
• W4382806979 hasRelatedWork W3046481916 @default.
• W4382806979 hasRelatedWork W3196960728 @default.
• W4382806979 hasRelatedWork W4229863258 @default.
• W4382806979 hasVolume "34" @default.
• W4382806979 isParatext "false" @default.
• W4382806979 isRetracted "false" @default.
• W4382806979 workType "article" @default.